- Home
- CYTK vs ATGE Comparison
CYTK vs ATGE Comparison
Compare CYTK & ATGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTK
- ATGE
- Stock Information
- Founded
- CYTK 1997
- ATGE 1987
- Country
- CYTK United States
- ATGE United States
- Employees
- CYTK N/A
- ATGE N/A
- Industry
- CYTK Biotechnology: Pharmaceutical Preparations
- ATGE Other Consumer Services
- Sector
- CYTK Health Care
- ATGE Consumer Discretionary
- Exchange
- CYTK Nasdaq
- ATGE Nasdaq
- Market Cap
- CYTK 4.6B
- ATGE 5.5B
- IPO Year
- CYTK 2004
- ATGE 1991
- Fundamental
- Price
- CYTK $59.89
- ATGE $144.89
- Analyst Decision
- CYTK Buy
- ATGE Strong Buy
- Analyst Count
- CYTK 16
- ATGE 3
- Target Price
- CYTK $76.73
- ATGE $139.00
- AVG Volume (30 Days)
- CYTK 2.5M
- ATGE 377.2K
- Earning Date
- CYTK 11-05-2025
- ATGE 10-30-2025
- Dividend Yield
- CYTK N/A
- ATGE N/A
- EPS Growth
- CYTK N/A
- ATGE 82.07
- EPS
- CYTK N/A
- ATGE 6.18
- Revenue
- CYTK $85,738,000.00
- ATGE $1,788,290,000.00
- Revenue This Year
- CYTK $363.61
- ATGE $9.77
- Revenue Next Year
- CYTK $64.08
- ATGE $6.32
- P/E Ratio
- CYTK N/A
- ATGE $24.69
- Revenue Growth
- CYTK 2635.74
- ATGE 12.85
- 52 Week Low
- CYTK $29.31
- ATGE $71.09
- 52 Week High
- CYTK $61.19
- ATGE $155.39
- Technical
- Relative Strength Index (RSI)
- CYTK 75.04
- ATGE 54.35
- Support Level
- CYTK $47.22
- ATGE $147.85
- Resistance Level
- CYTK $50.78
- ATGE $151.36
- Average True Range (ATR)
- CYTK 2.30
- ATGE 3.99
- MACD
- CYTK 0.66
- ATGE -0.53
- Stochastic Oscillator
- CYTK 90.55
- ATGE 40.12
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
About ATGE Adtalem Global Education Inc.
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.